Search results for " Follow-up"

showing 10 items of 229 documents

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Clinical analysis following lumbar interspinous devices implant: where we are and where we go

2014

Objectives:We present our experience with patients treated with interspinous devices who are affected by neurogenic intermittent claudication (NIC) or lumbar disc herniation (LDH) where the interspinous system has been inserted following microdiscectomy.Study design:Retrospective study.Methods:This study included patients (n=100) with NIC secondary to lumbar spinal stenosis (group 1), and patients (n=100) with LDH (group 2) in whom the interspinous device has been implanted following radicular decompression in a period spanning 6 years. The latter have been compared with a homogenous group of patients (n=100) where no interspinous system has been implanted following microdiscectomy (group 3…

AdultMaleReoperationMicrosurgerymedicine.medical_specialtyTime FactorsVisual analogue scaleDecompressionlumbar interspinous devicesAdult Prostheses and Implants Aged Decompression Surgical Disability Evaluation Female Follow-Up Studies Intermittent Claudication Intervertebral Disc Displacement Humans Lumbar Vertebrae Microsurgery Minimally Invasive Surgical Procedures Middle Aged Male Retrospective Studies Pain Measurement Patient Satisfaction Surveys and Questionnaires Reoperation Recurrence Treatment Outcome Spinal StenosisDisability EvaluationSpinal StenosisLumbarRecurrenceSurveys and QuestionnairesmedicineHumansMinimally Invasive Surgical ProceduresAgedPain MeasurementRetrospective StudiesLumbar VertebraeSettore MED/27 - Neurochirurgiabusiness.industryLumbar spinal stenosisProstheses and ImplantsGeneral MedicineIntermittent ClaudicationMiddle AgedDecompression Surgicalmedicine.diseaseIntermittent claudicationOswestry Disability IndexSurgeryTreatment OutcomeNeurologyPatient SatisfactionFemaleNeurology (clinical)Implantmedicine.symptombusinessClaudicationIntervertebral Disc DisplacementFollow-Up StudiesSpinal Cord
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Elective segmental ureterectomy for transitional cell carcinoma of the ureter: Long-term follow-up in a series of 73 patients

2012

What's known on the subject? and What does the study add? Upper Urinary Tract (UUT) Transitional Cell Carcinoma (TCC) is an uncommon disease and represents approximately 5% of all urothelial carcinomas. We report our series on 73 patients treated with Kidney Sparing Surgery for UUT TCC. Good results have been achieved in terms of oncological outcome comparing this conservative approach to the radical nephrourectomy. OBJECTIVES: • To report the long-term oncological outcome in patients with transitional cell carcinoma of the ureter electively treated with kidney-sparing surgery. • To compare our data with the few series reported in the literature. PATIENTS AND METHODS: • We considered 73 pat…

MaleTime FactorsTime FactorBiopsyUrologyConservative treatment; Segmental ureterectomy; Transitional cell carcinoma; Upper urinary tract; Ureter; Aged; Aged 80 and over; Biopsy; Carcinoma Transitional Cell; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Prospective Studies; Survival Rate; Time Factors; Treatment Outcome; Ureter; Ureteral Neoplasms; Ureteroscopy; Urologic Surgical Procedures; UrologyFollow-Up StudieTransitional cell carcinoma80 and overUreteroscopyHumansProspective StudiesAgedAged 80 and overCarcinoma Transitional CellElective Surgical ProcedureUreteral NeoplasmsCarcinomaMiddle AgedUreteral NeoplasmSurvival RateConservative treatment; Segmental ureterectomy; Transitional cell carcinoma; Upper urinary tract; UreterProspective StudieTreatment OutcomeItalyElective Surgical ProceduresUrologic Surgical ProcedureUpper urinary tractUrologic Surgical ProceduresSegmental ureterectomyFemaleTransitional CellUreterConservative treatmentFollow-Up StudiesHuman
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

2020

Background and Purpose— We aimed to determine the safety and mortality after mechanical thrombectomy in patients taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Methods— In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and meta-analysis of literature on this to…

MaleMESH: RegistriesAdministration Oral030204 cardiovascular system & hematology0302 clinical medicineInterquartile rangeMESH: ThrombectomyRegistriesStrokeThrombectomyMESH: AgedMESH: Middle AgedMESH: Follow-Up StudiesMiddle Aged3. Good healthddc:StrokeMESH: Administration OralFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cardiology and Cardiovascular MedicineMESH: Intracranial HemorrhagesCohort studymedicine.medical_specialty610 Medicine & healthMESH: AnticoagulantsLower riskMESH: Stroke03 medical and health sciencesMeta-Analysis as TopicInternal medicinemedicineHumansMESH: Meta-Analysis as TopicMedical prescriptionAgedAdvanced and Specialized NursingMESH: Humansbusiness.industryAnticoagulantsOdds ratiomedicine.diseaseFactor Xa inhibitorsMESH: MaleStroke treatmentIntracranial hemorrhagesObservational studyNeurology (clinical)MESH: Systematic Reviews as TopicbusinessMESH: Female030217 neurology & neurosurgeryFollow-Up StudiesSystematic Reviews as Topic
researchProduct

Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia

2016

Introduction. Since 2014 Delamanid (Dlm) was introduced in M/XDR-TB treatment under programmatic conditions. The aim of this study was to analyse experience of Dlm use. Methods. For all MDR-TB cases treatment regimens (Tx) are designed by MDR-TB expert committee. Dlm is prescribed for patients with risk of failure of Tx due to resistance or severe intolerance of key 2 nd line drugs. We analysed clinical and demographic data for all patients who received Dlm during the period of July 2014 to February 2016. Data were collected from patient9s medical records. Results. In total 20 MDR TB patients received Dlm: 3 female and 17 male with median age 46 years, including 2 children (11 and 13 years …

Pediatricsmedicine.medical_specialtybusiness.industryMedical recordPyrazinamidechemistry.chemical_compoundchemistryLevofloxacinMoxifloxacinLinezolidMedicineLost to follow-upDelamanidbusinessAdverse effectmedicine.drug10.2 Tuberculosis
researchProduct

The rationale for and practice of EIA follow-up: an analysis of Finnish road projects

2015

Follow-up is often considered to be a weak or even missing element in environmental impact assessment (EIA). Though it is recognized that follow-up practices could provide useful opportunities to learn from projects’ actual consequences, the practice is criticized for not achieving this goal. In this paper, we aim to clarify the relationship between the theoretical rationale for EIA follow-up and the actual practices carried out in a Finnish EIA context. An empirical analysis was performed with follow-up documents. The findings indicate that follow-ups focused on dealing with environmental impacts related to the physical environment, e.g., flora, fauna, and ground and surface waters. Social…

business.industryImpact evaluationta1172impact evaluationGeography Planning and DevelopmentEnvironmental resource managementContext (language use)Management Monitoring Policy and LawmonitoringPolitical scienceEIA follow-upEnvironmental impact assessmentElement (criminal law)businessEnvironmental planningImpact Assessment and Project Appraisal
researchProduct

1088 Minimally-invasive pelvic exenteration: a survival analysis

2021

Minimally-invasive pelvic exenteration: a survival analysis. Introduction/Background* Pelvic exenteration for recurrent and persistent gynecological malignancies is traditionally performed with open approach (OA). Nevertheless, reports on the use of minimally-invasive surgical (MIS) approach to pelvic exenteration have been published with promising results in terms of peri-operative morbidity. However, oncological safety of this approach has been poorly investigated. The aim of the present study was to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing minimally-invasive pelvic exenteration. Methodology All patients undergoing pelvic exenteration for gyn…

medicine.medical_specialtyMultivariate analysisSurgical approachPelvic exenterationbusiness.industryProportional hazards modelAdjuvant chemotherapymedicine.medical_treatmentSurgeryMedian follow-upMedicinebusinessGrading (tumors)Survival analysisMiscellaneous
researchProduct